HRMY
Price
$33.57
Change
-$0.08 (-0.24%)
Updated
Mar 12, 02:44 PM (EDT)
Capitalization
1.93B
55 days until earnings call
INCY
Price
$68.07
Change
-$3.06 (-4.30%)
Updated
Mar 11 closing price
Capitalization
13.17B
55 days until earnings call
Ad is loading...

HRMY vs INCY

Header iconHRMY vs INCY Comparison
Open Charts HRMY vs INCYBanner chart's image
Harmony Biosciences Holdings
Price$33.57
Change-$0.08 (-0.24%)
Volume$100
Capitalization1.93B
Incyte
Price$68.07
Change-$3.06 (-4.30%)
Volume$1.63M
Capitalization13.17B
HRMY vs INCY Comparison Chart
Loading...
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HRMY vs. INCY commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRMY is a Hold and INCY is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (HRMY: $33.65 vs. INCY: $68.07)
Brand notoriety: HRMY: Not notable vs. INCY: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HRMY: 100% vs. INCY: 99%
Market capitalization -- HRMY: $1.93B vs. INCY: $13.17B
HRMY [@Biotechnology] is valued at $1.93B. INCY’s [@Biotechnology] market capitalization is $13.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HRMY’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s).

  • HRMY’s FA Score: 0 green, 5 red.
  • INCY’s FA Score: 1 green, 4 red.
According to our system of comparison, INCY is a better buy in the long-term than HRMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HRMY’s TA Score shows that 3 TA indicator(s) are bullish while INCY’s TA Score has 3 bullish TA indicator(s).

  • HRMY’s TA Score: 3 bullish, 5 bearish.
  • INCY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both HRMY and INCY are a bad buy in the short-term.

Price Growth

HRMY (@Biotechnology) experienced а +3.19% price change this week, while INCY (@Biotechnology) price change was -2.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.47%. For the same industry, the average monthly price growth was -7.02%, and the average quarterly price growth was -8.34%.

Reported Earning Dates

HRMY is expected to report earnings on May 06, 2025.

INCY is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($13.2B) has a higher market cap than HRMY($1.93B). INCY has higher P/E ratio than HRMY: INCY (453.60) vs HRMY (13.39). INCY YTD gains are higher at: -1.448 vs. HRMY (-2.209). INCY has higher annual earnings (EBITDA): 408M vs. HRMY (233M). INCY has more cash in the bank: 2.16B vs. HRMY (467M). INCY has less debt than HRMY: INCY (43.5M) vs HRMY (179M). INCY has higher revenues than HRMY: INCY (4.24B) vs HRMY (715M).
HRMYINCYHRMY / INCY
Capitalization1.93B13.2B15%
EBITDA233M408M57%
Gain YTD-2.209-1.448153%
P/E Ratio13.39453.603%
Revenue715M4.24B17%
Total Cash467M2.16B22%
Total Debt179M43.5M411%
FUNDAMENTALS RATINGS
INCY: Fundamental Ratings
INCY
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HRMYINCY
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
66%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
60%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
63%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
62%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
61%
Declines
ODDS (%)
Bearish Trend 14 days ago
76%
Bearish Trend 9 days ago
63%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
N/A
View a ticker or compare two or three
Ad is loading...
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X82862.2100004330.211000
+5.51%
Bitcoin cryptocurrency
TSLA230.588.43
+3.79%
Tesla
GME22.610.19
+0.85%
GameStop Corp
SPY555.92-4.66
-0.83%
SPDR® S&P 500® ETF Trust
AAPL220.84-6.64
-2.92%
Apple

HRMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with GSGTF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then GSGTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
-2.27%
GSGTF - HRMY
44%
Loosely correlated
N/A
SAGE - HRMY
39%
Loosely correlated
+1.79%
ANAB - HRMY
38%
Loosely correlated
+4.84%
SPHDF - HRMY
34%
Loosely correlated
+69.85%
INCY - HRMY
32%
Poorly correlated
-4.30%
More

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with RPRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then RPRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-4.30%
RPRX - INCY
37%
Loosely correlated
-0.89%
PLRX - INCY
36%
Loosely correlated
+9.44%
ZYME - INCY
33%
Loosely correlated
+5.41%
RVMD - INCY
33%
Loosely correlated
+5.62%
REGN - INCY
33%
Poorly correlated
-3.58%
More